SLC5A2 and obstructive sleep apnea syndrome: Additional evidence of the favorable impact on the pathophysiology of OSA arises from the established influence of SGLT2 inhibitors on visceral and subcutaneous adipose tissue, as demonstrated in previous studies [76,77,78].